An open, non-comparative evaluation of the efficacy and safety of amphotericin B lipid complex as treatment of neutropenic patients with presumed or confirmed pulmonary fungal infections.
Myint
H
H
Kyi
A A
AA
Winn
R M
RM
D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004341:Drug Evaluation; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced; D008168:Lung / Q000187:drug effects / Q000382:microbiology; D008172:Lung Diseases, Fungal / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010715:Phosphatidylglycerols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000935:Antifungal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B